Kupando

Executive Summary

Kupando is a German biopharmaceutical company pioneering first-in-class, small molecule dual Toll-Like Receptor (TLR) agonists to address critical unmet needs in oncology and infectious diseases. Founded in 2019 and headquartered in Munich, the company is advancing its lead candidate, KUP101, which activates innate and trained immunity. This novel mechanism is designed to combat treatment-resistant cancers and antimicrobial-resistant (AMR) infections, two areas with significant therapeutic gaps. By simultaneously engaging multiple TLR pathways, KUP101 aims to induce robust and durable immune responses, potentially offering advantages over single-target immunotherapies. Currently in the pre-clinical stage, Kupando is positioned to enter formal IND-enabling studies, with an emphasis on demonstrating safety and efficacy in relevant animal models. The company's focus on dual TLR agonism represents a innovative approach within the immuno-oncology and anti-infective landscapes, attracting interest for its potential to synergize with existing therapies like checkpoint inhibitors. With a lean team and a focused pipeline, Kupando exemplifies the early-stage biotech model, relying on scientific differentiation to drive value.

Upcoming Catalysts (preview)

• Q3 2026IND-enabling study completion and IND filing for KUP10130% success
• Q2 2026Preclinical proof-of-concept data in cancer or AMR models50% success
• Q4 2026Series A financing or strategic partnership40% success